RE: Short8 Jul 2021 19:06
Well it's all turned a bit sour from when we got our CV results and hit £2.80. Then Conifer starts to exit and now Jupiter opens a short (**** timing mind you, should've done it at £2.50 or so)
SP is probably undervalued but can also be justified due to lack of known progress. I'll be honest I expected a flurry of RNS's in succession after various inflection points from even before initial CV, full CV, MHRA, CE and now delta variant detection - yet all we have is one distributor and promise of continued 'talks'. External factors aren't doing us any favours either with the Innova *******s, lockdown ending, vaccines taking priority, UK diagnostic industry being turned away, talks of letting COVID run riot etc
All in all I had much higher expectations dating over a year back now, they've obviously not yet been met and I can't complain too much about where we're at give or take 20/30% on the SP.
As for the positives, I do believe they're trying and I do believe the market remains substantial despite the U-turns left right and centre on LFD testing requirements. There is no way a best in class test does not sell in this environment, but production needs to be ramped up ASAP and hopefully some big deals are being worked in terms of end users (a few airlines or EU countries will do nicely). Hopefully we'll hear of these over the next few weeks.
Bit miffed on timing but despite the rollercoaster of a journey, we do have a best in class test verified, approved and detects Delta, so surprisingly the multi-bag opportunity remains. The key inflection points:
- 35 - 60m capacity
- Home use
- Large end user deals
- Government contract?
- Affimer licensing
- AV6K
- That short will also have to be closed at some point so expect a small rally
As ever with AVCT, sentiment can switch within a second and the SP does move fast so keep your heads up!
Sign In
Follow the stocks
